Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.

Oncotarget - 27 Jun 2017

Lin Tzu-Chi, Chen Syue-Ting, Huang Min-Chuan, Huang John, Hsu Chia-Lang, Juan Hsueh-Fen, Lin Ho-Hsiung, Chen Chi-Hau

Abstract excerpt

Ovarian cancer is the most lethal of the gynecologic malignancies. N-acetylgalactosaminyltransferase 6 (GALNT6), an enzyme that mediates the initial step of mucin type-O glycosylation, has been reported to regulate mammary carcinogenesis. However, the expression and role of GALNT6 in ovarian cancer are still unclear. Here we showed that high GALNT6 expression correlates with increased recurrence, lymph node...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockdown Techniques

Share to N-Acetylgalactosaminyltransferases

Share to Ovarian Neoplasms

Share to Phenotype

Share to Polypeptide N-acetylgalactosaminyltransferase

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 28388560
DOI: 10.18632/oncotarget.16585
PMCID: PMC5522090

Genes

GALNT6
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.PMID 28388560Read ↗

Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.Semantic proximity Read ↗

N‐acetylgalactosaminyltransferase GALNT6 is a potential therapeutic target of clear cell renal cell carcinoma progressionSemantic proximity Read ↗

GALNT6 promotes bladder cancer malignancy and immune escape by epithelial-mesenchymal transition and CD8+T cellsSemantic proximity Read ↗

A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancerSemantic proximity Read ↗

Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression.Semantic proximity Read ↗

GALNT1 Enhances Malignant Phenotype of Gastric Cancer via Modulating CD44 Glycosylation to Activate the Wnt/β-catenin Signaling Pathway.Semantic proximity Read ↗

Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.Semantic proximity Read ↗

GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.Semantic proximity Read ↗

Inhibition of PTK6 Hinders the Growth and Migration of Ovarian Cancer and Its Potential Clinical SignificanceSemantic proximity Read ↗

N-glycosylation of GSTO1 promotes cervical cancer migration and invasion through JAK/STAT3 pathway activationSemantic proximity Read ↗

GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.Semantic proximity Read ↗

Altered glycosylation of several metastasis-associated glycoproteins with terminal GalNAc defines the highly invasive cancer cell phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.